FGEN James A Schoeneck buys $88K worth of shares
Mar 25, 2025, 4:34 AM
0.00%
What does FGEN do
FibroGen, headquartered in San Francisco, focuses on developing novel therapeutics for cancer and anemia, with key products including Pamrevlumab and Roxadustat. The company went public on November 14, 2014, and employs 486 staff.
James A Schoeneck bought 250,000 shares of FGEN on 20 March at $0.35 per share, worth a total of $88K. They now own 323,722 FGEN shares, or a 339% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.